Navigation Links
TGen's Huentelman and Weiss named to 2013 Class of 40 Under 40

PHOENIX, Ariz. June 5, 2013 Dr. Matt Huentelman of the Translational Genomics Research Institute (TGen) and Dr. Glen Weiss of TGen and Cancer Treatment Centers of America (CTCA) are among the 40 business leaders under 40 years of age named by the Phoenix Business Journal to its 13th Annual Class of 40 Under 40.

They will be honored at an awards ceremony June 27 at the Phoenix Art Museum.

Dr. Huentelman, Ph.D., is an Associate Professor in TGen's Neurogenomics Division, where he oversees research programs focused on sensory disorders, including hearing and vision loss, and on aging and age-related diseases, such as Alzheimer's disease and the genetics of learning and memory highlighted recently by the launch of TGen's MindCrowd project (

Dr. Huentelman also is the Co-Director of TGen's Center for Rare Childhood Disorders, which investigates uncommon neurologic problems among children, often those that are only a collection of symptoms with no diagnosis.

"I am honored to be selected among the 40 Under 40 by the Phoenix Business Journal," Dr. Huentelman said. "This recognition serves to highlight the significant advances that TGen has made through the study of the human genome, and the insights and breakthroughs being made, not only by me, but by our entire scientific staff every day."

Dr. Weiss, M.D., is a Clinical Associate Professor in TGen's Cancer and Cell Biology Division and is Director of Clinical Research at CTCA. His research focuses on genomic and other 'omics characterizations of lung cancer, rare cancers and early-detection strategies.

Dr. Weiss has been selected by CTCA at Western Regional Medical Center to head the startup of a new clinical research program in Goodyear, Ariz. Dr. Weiss is also Co-Unit Head of TGen's Lung Cancer Research Laboratory.

"As a research scientist, being a member of the 40 Under 40 is a reflection of the collaborations I am privileged to conduct through TGen and CTCA," Dr. Weiss said. "As a medical doctor, these collaborations lead to new therapies that can help the patients that look to us for healing and hope."

The 40 Under 40 program's hundreds of alumni includes Phoenix Mayor Greg Stanton, a member of the TGen Board of Directors, and Arizona Diamondbacks President Derrick Hall, a member of TGen's National Advisory Council for Pancreatic Cancer Research.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. LSUHSCs Weiss chosen to help set national eye policy, research
2. Carnegies Greg Asner named Energy/Climate Fellow by US State Department
3. John A. Kaufman named 2012 Dotter Lecturer by Society of Interventional Radiology Foundation
4. Researchers aim to assemble the tree of life for all 2 million named species
5. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
6. Top young Latin-American scientists named Pew Biomedical Fellows
7. Kendall L. Carder named recipient of the Jerlov Award
8. Winners named in 2012 AAAS Kavli Science Journalism Award Competition
9. Michael Barnett of Boston College named Professor of the Year for Massachusetts
10. Cultural anthropologist Mark Flinn named 2013 AAAS Fellow
11. Kansas State University scientists named American Association for the Advancement of Science fellows
Post Your Comments:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: